Brief: JCR Pharmaceuticals Announces Completion Of Clinical Trial Notification Process In Japan For Phase I Study Of JR-441 For Mucopolysaccharidosis Type IIIA
03/09/2024 20:53
Sept 3 (Reuters) - JCR Pharmaceuticals Co Ltd 4552.T :
* JCR PHARMACEUTICALS ANNOUNCES COMPLETION OF CLINICAL TRIAL
NOTIFICATION PROCESS IN JAPAN FOR PHASE I STUDY OF JR-441 FOR
MUCOPOLYSACCHARIDOSIS TYPE IIIA
* JCR PHARMACEUTICALS- MINOR IMPACT ON JCR'S FINANCIAL
RESULTS FOR
FY FROM ANNOUNCEMENT
Source text for Eikon: ID:nBw9sY87ca
Further company coverage: 4552.T
((Reuters.Briefs@thomsonreuters.com;))
Recent news on JCR Pharmaceuticals
See all newsBrief: JCR Pharmaceuticals Receives Marketing Authorization In Kuwait For Izcargo
Italfarmaco And Jcr Pharmaceuticals Enter Into Exclusive License Agreement For Jr-141 In United States, Europe, And Latin America
Brief: Jcr Pharmaceuticals Receives Orphan Drug Designation For Givinostat In Japan
Brief: Medipal & JCR Dose First Patient In Global Phase I/II Trial OF JR-446 For Mucopolysaccharidosis Type IIIB
Table: Jcr Pharmaceuticals -Q1 group results